Assenagon Asset Management S.A. Sells 52,123 Shares of Enanta Pharmaceuticals, Inc. $ENTA

Assenagon Asset Management S.A. decreased its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 49.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 54,257 shares of the biotechnology company’s stock after selling 52,123 shares during the quarter. Assenagon Asset Management S.A. owned 0.25% of Enanta Pharmaceuticals worth $649,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its stake in shares of Enanta Pharmaceuticals by 3.2% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 159,801 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 4,974 shares during the last quarter. Invesco Ltd. increased its stake in Enanta Pharmaceuticals by 29.3% in the first quarter. Invesco Ltd. now owns 60,277 shares of the biotechnology company’s stock valued at $333,000 after purchasing an additional 13,663 shares in the last quarter. Nuveen LLC bought a new stake in Enanta Pharmaceuticals in the first quarter valued at approximately $313,000. American Century Companies Inc. raised its holdings in Enanta Pharmaceuticals by 8.2% in the first quarter. American Century Companies Inc. now owns 40,004 shares of the biotechnology company’s stock worth $221,000 after purchasing an additional 3,042 shares during the period. Finally, Walleye Capital LLC boosted its position in shares of Enanta Pharmaceuticals by 63.8% during the first quarter. Walleye Capital LLC now owns 27,318 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 10,639 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, insider Yat Sun Or sold 2,390 shares of the business’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $14.23, for a total transaction of $34,009.70. Following the completion of the transaction, the insider directly owned 371,392 shares in the company, valued at $5,284,908.16. The trade was a 0.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Tara Lynn Kieffer sold 2,106 shares of the firm’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $14.23, for a total value of $29,968.38. Following the completion of the sale, the insider directly owned 30,620 shares in the company, valued at approximately $435,722.60. This represents a 6.44% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 11,961 shares of company stock worth $170,149. Corporate insiders own 13.89% of the company’s stock.

Enanta Pharmaceuticals Price Performance

ENTA stock opened at $16.60 on Friday. Enanta Pharmaceuticals, Inc. has a one year low of $4.09 and a one year high of $17.05. The stock has a market cap of $479.08 million, a price-to-earnings ratio of -4.33 and a beta of 0.96. The company has a fifty day moving average price of $12.91 and a two-hundred day moving average price of $9.89.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Monday, November 17th. The biotechnology company reported ($0.87) EPS for the quarter, beating analysts’ consensus estimates of ($1.13) by $0.26. The firm had revenue of $15.13 million for the quarter, compared to analyst estimates of $15.60 million. Enanta Pharmaceuticals had a negative return on equity of 93.76% and a negative net margin of 125.36%. Research analysts anticipate that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

Analysts Set New Price Targets

ENTA has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Enanta Pharmaceuticals in a research report on Friday, November 14th. They issued an “overweight” rating and a $17.00 price objective for the company. Westpark Capital increased their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, September 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Wednesday, October 8th. Evercore ISI lowered their target price on Enanta Pharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research note on Monday, September 15th. Finally, Jefferies Financial Group upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating and raised their target price for the stock from $14.00 to $20.00 in a report on Wednesday, October 1st. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $20.33.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.